Details For Selected Brain Tumor Treatment

Sponsored By

Please Click On The Above Banner For More Details

Last updated refers to the date when our listing for each treatment was last updated.
ID is our internal ID - starting with VT.
Min Karnofsky is a general guide to how well you have to function to use this treatment
For trials that also have a NCT number, you can click that number to pop up the listing from the clinicaltrials.gov website.



		Treatment Name:		MGH 99-114. A phase II study of systemic topotecan in patients with CNS metastatic carcinoma

		Keywords:		Topotecan

		Phase:		Phase 2

		Treatment ID#s:		VT818 Brain mets

		Age Group:		Adults Only

		Min Karnofsky Score:		60: Requires occasional assistance but is able to care for most of own needs

		Conditions:		Newly Diagnosed: Y Recurrent: Y Prior Surgery is Allowed Prior Radiation is Allowed Prior Chemotherapy is Allowed This is for recurrent CNS brain mets. Patients must have received whole brain radiation therapy prior to entry onto this trial. Patients may not receive concurrent chemotherapy. KPS > or equal to 60. Patients must be on a stable dose of steroids for > or equal to 7 days before starting therapy. No active infections. Must have adequate marrow function.

		Last Updated:		11/26/2005

		Tumor Types:		Metastatic Brain Tumor


		Comments:

		Treatment Type:		Chemotherapy.

		Contact:		Mass. General Hospital - Brain Tumor Center Jean E. Kracher Executive Director Suite 315, Cox Building Boston, MA 02114 Phone:(617)724-8870 Fax: (617)724-8769 Click here to send an email Website: brain.mgh.harvard.edu/